Abstract
Background Primary progressive aphasia (PPA) is a debilitating neurodegenerative disease that primarily impairs language function. It is comprised of three subtypes with varied clinical presentation and cortical atrophy patterns: logopenic variant (lvPPA), non-fluent variant (nfvPPA), and semantic variant (svPPA). No prior work has examined differences in brain chemistry between the PPA subtypes, or associations of brain chemistry with symptom severity.
Methods We collected magnetic resonance spectroscopy (MRS) data in the left inferior frontal gyrus (IFG, a main language production region) and the right sensorimotor cortex (SMC) from 61 PPA patients. We analyzed tissue-corrected metabolite levels to account for the effects of cortical atrophy and other tissue-specific properties. We aimed to: 1) characterize differences between PPA subtypes for 5 brain metabolites: total N-acetylaspartate (tNAA), total choline (tCho), total creatine (tCr), glutamate+glutamine (Glx), and gamma-aminobutyric acid (GABA); and 2) test for associations between these neurometabolites and PPA symptom severity.
Results tCr levels differed by PPA subtype across both the left IFG and right SMC. In both regions, tCr levels were lowest among lvPPA patients and highest among svPPA patients. Moreover, across the whole cohort, higher tCr and lower Glx levels in the left IFG correlated with greater disease severity.
Conclusions Given that tCr is involved in brain energy metabolism and homeostasis, our results indicate that svPPA pathology might involve changes in specific cellular energy processes. Moreover, our finding that higher tCr was associated with worse PPA symptom severity suggests that perturbations to cellular energy homeostasis in cortical language areas may contribute to PPA symptoms. In addition, reduced cortical excitatory capacity (i.e., lower Glx) in brain areas related to language processing may also contribute to PPA symptoms. Together, these findings suggest that tCr could serve as a biomarker to differentiate between PPA subtypes, and that both tCr and Glx might have utility for better understanding PPA disease mechanisms and tracking disease progression.
Trial registration ClinicalTrials.gov (NCT02606422). Registered 11 November 2015 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02606422?term=NCT02606422&draw=2&rank=1
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Institute on Aging (K00 AG068440-03 to KH, R00 AG062230 to GO, and R01 DC014475-05 and R01 AG068881-02 to KT) and grants from the National Institute of Biomedical Imaging and Bioengineering (R01 EB016089 to RE, and P41 EB031771).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Johns Hopkins University Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The raw data supporting the conclusions of this manuscript will be made available by the authors without undue reservation.
Abbreviations
- PPA
- Primary progressive aphasia
- lvPPA
- logopenic variant PPA
- nfvPPA
- non-fluent variant PPA
- svPPA
- semantic variant PPA
- MRS
- magnetic resonance spectroscopy
- IFG
- inferior frontal gyrus
- SMC
- sensorimotor cortex
- tNAA
- total N-acetylaspartate
- tCho
- total choline
- tCr
- total creatine
- Glx
- glutamate+glutamine
- GABA
- gamma-aminobutyric acid
- AD
- Alzheimer’s disease
- TE
- echo time
- PRESS
- Point RESolved Spectroscopy
- NAAG
- N-acetylaspartylglutamate
- PCh
- phosphocholine
- GPC
- glycerophosphocholine
- MEGA-PRESS
- MEscher–GArwood Point RESolved Spectroscopy
- MCI
- mild cognitive impairment
- tDCS
- transcranial direct current stimulation
- FTD-CDR
- FrontoTemporal Dementia Clinical Dementia Rating Scale
- MPRAGE
- magnetization-prepared rapid gradient-echo
- HSVD
- Hankel singular value decomposition
- MMs
- macromolecules
- Cr
- creatine
- PCr
- phosphocreatine
- ATP
- adenosine triphosphate
- ADP
- adenosine diphosphate
- AGAT
- glycine amidinotransferase
- GAMT
- guanidinoacetate methyltransferase
- SNPH
- syntaphilin
